Alto Neuroscience (NYSE:ANRO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Alto Neuroscience (NYSE:ANRO) from a strong sell rating to a sell rating in a research report report published on Saturday.

A number of other research firms have also recently commented on ANRO. Weiss Ratings upgraded Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. Wolfe Research initiated coverage on shares of Alto Neuroscience in a report on Friday, May 22nd. They set an “outperform” rating for the company. Robert W. Baird lowered their price objective on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. JonesTrading dropped their target price on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research note on Thursday, April 2nd. Finally, HC Wainwright restated a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Stock Performance

NYSE ANRO opened at $26.00 on Friday. Alto Neuroscience has a 1 year low of $2.72 and a 1 year high of $28.85. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. The company has a fifty day moving average price of $23.20 and a 200-day moving average price of $21.26. The firm has a market cap of $912.38 million, a price-to-earnings ratio of -10.74 and a beta of 1.04.

Alto Neuroscience (NYSE:ANRO) last released its earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, equities research analysts predict that Alto Neuroscience will post -3.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

Several hedge funds have recently made changes to their positions in the stock. Torren Management LLC purchased a new stake in shares of Alto Neuroscience in the fourth quarter worth about $62,000. GK Wealth Management LLC bought a new position in shares of Alto Neuroscience in the second quarter worth approximately $226,000. Balyasny Asset Management L.P. bought a new position in shares of Alto Neuroscience in the fourth quarter worth approximately $198,000. OMERS ADMINISTRATION Corp purchased a new stake in Alto Neuroscience in the fourth quarter valued at approximately $221,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Alto Neuroscience in the 4th quarter worth approximately $304,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.